DelveInsight’s “Interstitial Cystitis – Market Insights, Epidemiology and Market Forecast-2023” Reports provides an overview of the disease and global market trends of the Interstitial Cystitis for the seven major markets i.e. United States, Europe (France, Germany, Italy, Spain, UK) and Japan. The Report covers the therapeutics market revenue, treatment practice and Interstitial Cystitis forecasted market share from 2017 to 2023 segmented by seven major markets. In addition, the report also includes global forecast of epidemiology of Interstitial Cystitis till 2023.
Interstitial cystitis (IC) also known as painful bladder syndrome is a chronic disease that results in recurring discomfort or pain in the bladder and the surrounding pelvic region. This is considered as multiple bladder condition as it can lead to many other problems.
Current studies estimate that 2.7% to 6.5% of women in the United States have symptoms consistent with a diagnosis of interstitial cystitis/bladder pain syndrome (IC/BPS). PBS/IC is more common in women, with a female/male ratio that ranges from 5:1 to 10:1 and the Median age at diagnosis is 42 to 46 yr old whereas men are diagnosed at a younger age.
According to DelveInsight, the Interstitial Cystitis market for 7MM is estimated to be USD 427.2 Million by 2023 at a CAGR of (XX%). The number of Incident Probable IC cases is expected to reach 197,086 cases in 2023.
The report is built using data and information sourced from proprietary databases, primary and secondary research and in-house Forecast model analysis by Publisher team of industry experts.
Scope
• The report will help in developing business strategies by understanding the trends shaping and driving the global Interstitial Cystitis market.
• Organize sales and marketing efforts by identifying the best opportunities for Interstitial Cystitis in US, Europe (Germany, Spain, Italy, France and United Kingdom) and Japan.
• To understand the future market competition in the global Interstitial Cystitis market and Insightful review of the key market drivers and barriers.
• To understand the regulatory scenario in major markets.
• The Report also covers the detailed global historical and forecasted Interstitial Cystitis market covering United States, Europe (Germany, Spain, Italy, France and United Kingdom) and Japan from 2013-2023.
'
Report Introduction
Interstitial Cystitis(IC)/ Bladder Pain Syndrome (BPS) Market Overview at a Glance
Global Market Size of IC/BPS in 2016
Global Market Size of IC/BPS in 2023
Interstitial Cystitis (IC)
Overview
Types
Cause
Pathophysiology
Symptoms
Risk Factor
Diagnosis
Medical devices
United States
Europe
Epidemiology and Patient Population
Assumptions and Caveats
Interstitial Cystitis(IC)/ Bladder Pain Syndrome (BPS) Geography wise Incident Probable IC Cases
7MM Incident Probable IC Cases in 2016
7MM Incident Probable IC Cases in 2023
United States
Incident Probable Cases of Interstitial Cystitis in United States
Europe
Germany
Incident Probable Cases of Interstitial Cystitis in Germany
Italy
Incident Probable Cases of Interstitial Cystitis in Italy
Spain
Incident Probable Cases of Interstitial Cystitis in Spain
France
Incident Probable Cases of Interstitial Cystitis in France
United Kingdom
Incident Probable Cases of Interstitial Cystitis in United Kingdom
Japan
Incident Cases of Interstitial Cystitis in Japan
Treatment Algorithm
United States
First Line Treatment
Second Line Treatment
Third Line Treatment
Fourth Line Treatment
Fifth line treatment
Sixth line treatment
Japan
Europe
Marketed Drugs
List of Marketed Drugs
Elmiron: Janssen Pharmaceutical
Regulatory Milestones
Advantages & Disadvantages
Safety and Efficacy of Elmiron
Side effects of Elmiron
Product Profile
SWOT Analysis of Elmiron
Marketed Medical Devices
RIMSO-50: Mylan Pharmaceutical
Advantages & Disadvantages
Product Profile
Safety and Efficacy of RIMSO-50
Side effects of RIMSO-50
Cystistat: Bioniche Life Sciences Inc
Advantages & Disadvantages
Product Profile
Safety and Efficacy of Cystistat
Side effects of Cystistat
Gepan instill: Pohl-Boskamp GmbH & Co
Advantages & Disadvantages
Product Profile
Safety and Efficacy of Gepan instill
Side effects of Gepan instill
Uracyst: Stellar Pharmaceuticals
Regulatory Milestones
Advantages & Disadvantages
Product Profile
Safety and Efficacy of Uracyst
Side effects of Uracyst
Hyacyst : Syner-Med Ltd
Advantages & Disadvantages
Product Profile
Side effects of Hyacyst
iAluRil: Aspire Pharma
Advantages & Disadvantages
Product Profile
Side effects of iAluRil
Emerging Therapies
Pipeline Drugs
AQX 1125: Aquinox
Regulatory Milestones
Clinical Development
Product Profile
Clinical Pipeline Activity
Ongoing Trials Information
Clinical Trial by Phase
SWOT Analysis
Mirabegron: Astellas Pharma
Clinical Development
Product Profile
Clinical Pipeline Activity
Ongoing Trials Information
Clinical Trial by Phase
SWOT Analysis
Market Size
Global Interstitial Cystitis Market Analysis
Overview of Global Interstitial Cystitis Market (2013-2023)
Total 7MM Interstitial Cystitis Market Analysis
Overview of Total Interstitial Cystitis Market (2013-2023)
Interstitial Cystitis(IC)/ Bladder Pain Syndrome (BPS) Region wise Market Analysis
Region wise Market Size (2016, 2023)
7MM Interstitial Cystitis: Country-Wise Market Analysis
Overview on Total Interstitial Cystitis Market (2016)
Overview on Total Interstitial Cystitis Market (2023)
Global Interstitial Cystitis: Market Analysis
United States Market Size
Europe Market Size
Germany Market Size
France Market Size
United Kingdom Market Size
Spain Market Size
Italy Market Size
Japan Market Size
Market Drivers
Market Barriers
Unmet Needs
Appendix
Report Methodology
Consulting Services
Disclaimer
About DelveInsight
List of Tables
Table 1: Incident Cases of Interstitial Cystitis in United States (2013-2023)
Table 2: Incident Cases of Interstitial Cystitis in Germany (2013-2023)
Table 3: Incident Cases of Interstitial Cystitis in Italy (2013-2023)
Table 4: Incident Cases of Interstitial Cystitis in Spain (2013-2023)
Table 5: Incident Cases of Interstitial Cystitis in France (2013-2023)
Table 6: Incident Cases of Interstitial Cystitis in United Kingdom (2013-2023)
Table 7: Incident Cases of Interstitial Cystitis in Japan (2013-2023)
Table 8: List of Phase III Drugs for Interstitial Cystitis
Table 9: AQX-1125, Clinical Trials by Zone, 2017
Table 10: Clinical Trials by Recruitment status, 2017
Table 11: Mirabegron, Clinical Trials by Zone, 2017
Table 12: Clinical Trials by Recruitment status, 2017
Table 13: Global Market Size of Interstitial Cystitis in USD, Million (2013-2023)
Table 14: Total 7 Major Market Size of Interstitial Cystitis in USD, Million (2013-2023)
Table 15: Region wise Market Size of Interstitial Cystitis in USD, Million (2013-2023)
Table 16: Total Interstitial Cystitis , Distribution share (2016) as per the 7MM
Table 17: Total Interstitial Cystitis , Distribution share (2023) as per the 7MM
Table 18: United States Market Size of Interstitial Cystitis in USD, Million (2013-2023)
Table 19: Germany Market Size of Interstitial Cystitis in USD, Million (2013-2023)
Table 20: France Market Size of Interstitial Cystitis in USD, Million (2013-2023)
Table 21: United Kingdom Market Size of Interstitial Cystitis in USD, Million (2013-2023)
Table 22: Spain Market Size of Interstitial Cystitis in USD, Million (2013-2023)
Table 23: Italy Market Size of Interstitial Cystitis in USD, Million (2013-2023)
Table 24: Japan Market Size of Interstitial Cystitis in USD, Million (2013-2023)
List of Figures
Figure 1: Pathophysiology for Interstitial Cystitis
Figure 2: Risk Factors for Interstitial Cystitis
Figure 4: Incident Probable Cases of Interstitial Cystitis in United States (2013-2023)
Figure 5: Incident Probable Cases of Interstitial Cystitis in Germany (2013-2023)
Figure 6: Incident Probable Cases of Interstitial Cystitis in Italy (2013-2023)
Figure 7: Incident Probable Cases of Interstitial Cystitis in Spain (2013-2023)
Figure 8: Incident Probable Cases of Interstitial Cystitis in France (2013-2023)
Figure 9: Incident Probable Cases of Interstitial Cystitis in United Kingdom (2013-2023)
Figure 10: Incident Probable Cases of Interstitial Cystitis in Japan (2013-2023)
Figure 11: Treatment Algorithm by American Urology association
Figure 12: Lines of Treatment by American Urology Association
Figure 13: AQX-1125, Clinical Trials by Zone (%), 2017
Figure 14: AQX-1125, Clinical Trials by Recruitment status (%), 2017
Figure 15: Mirabegron, Clinical Trials by Zone (%), 2017
Figure 16: Mirabegron, Clinical Trials by Recruitment status (%), 2017
Figure 17: Global Market Size of Interstitial Cystitis in USD, Million (2013-2023)
Figure 18: Total 7 Major Market Size of Interstitial Cystitis in USD, Million (2013-2023)
Figure 19: Region wise Market Size of Interstitial Cystitis in USD, Million (2013-2023)
Figure 20: Total 7 Major Market Size of Interstitial Cystitis in USD, Million (2016)
Figure 21: Total 7 Major Market Size of Interstitial Cystitis in USD, Million (2023)
Figure 22: United States Market Size of Interstitial Cystitis in USD, Million (2013-2023)
Figure 23: Germany Market Size of Interstitial Cystitis in USD, Million (2013-2023)
Figure 24: France Market Size of Interstitial Cystitis in USD, Million (2013-2023)
Figure 25: United Kingdom Market Size of Interstitial Cystitis in USD, Million (2013-2023)
Figure 26: Spain Market Size of Interstitial Cystitis in USD, Million (2013-2023)
Figure 27: Italy Market Size of Interstitial Cystitis in USD, Million (2013-2023)
Figure 28: Japan Market Size of Interstitial Cystitis in USD, Million (2013-2023)
Table 1: Incident Cases of Interstitial Cystitis in United States (2013-2023)
Table 2: Incident Cases of Interstitial Cystitis in Germany (2013-2023)
Table 3: Incident Cases of Interstitial Cystitis in Italy (2013-2023)
Table 4: Incident Cases of Interstitial Cystitis in Spain (2013-2023)
Table 5: Incident Cases of Interstitial Cystitis in France (2013-2023)
Table 6: Incident Cases of Interstitial Cystitis in United Kingdom (2013-2023)
Table 7: Incident Cases of Interstitial Cystitis in Japan (2013-2023)
Table 8: List of Phase III Drugs for Interstitial Cystitis
Table 9: AQX-1125, Clinical Trials by Zone, 2017
Table 10: Clinical Trials by Recruitment status, 2017
Table 11: Mirabegron, Clinical Trials by Zone, 2017
Table 12: Clinical Trials by Recruitment status, 2017
Table 13: Global Market Size of Interstitial Cystitis in USD, Million (2013-2023)
Table 14: Total 7 Major Market Size of Interstitial Cystitis in USD, Million (2013-2023)
Table 15: Region wise Market Size of Interstitial Cystitis in USD, Million (2013-2023)
Table 16: Total Interstitial Cystitis , Distribution share (2016) as per the 7MM
Table 17: Total Interstitial Cystitis , Distribution share (2023) as per the 7MM
Table 18: United States Market Size of Interstitial Cystitis in USD, Million (2013-2023)
Table 19: Germany Market Size of Interstitial Cystitis in USD, Million (2013-2023)
Table 20: France Market Size of Interstitial Cystitis in USD, Million (2013-2023)
Table 21: United Kingdom Market Size of Interstitial Cystitis in USD, Million (2013-2023)
Table 22: Spain Market Size of Interstitial Cystitis in USD, Million (2013-2023)
Table 23: Italy Market Size of Interstitial Cystitis in USD, Million (2013-2023)
Table 24: Japan Market Size of Interstitial Cystitis in USD, Million (2013-2023)
